^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CT120

    i
    Other names: CT120, autologous CD19/22 targeted CAR-T, CT120A
    Associations

    News

    Trials
    Company:
    IASO BIO
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2years
    CT120, a novel fully human anti-CD19 x anti-CD22 dual targeted chimeric antigen receptor T cell product for the treatment of B-NHL and B-ALL (AACR 2022)
    Collectively, CT120 is a potent and safe anti-CD19×anti-CD22 dual target CAR-T product for the treatment of B-NHL and B-ALL, and now it is in registered phase 1/2 clinical trial.
    CAR T-Cell Therapy
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
    |
    CT120